Transplantation Tolerance

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 487-497

  Newell, Kenneth A ^a   Larsen, Christian P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

alloreactivity; deletion; immune monitoring; regulation; T cells

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; CD3 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOGLOBULIN ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; AUTOIMMUNITY; CELL CULTURE; CLINICAL PRACTICE; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MONOTHERAPY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; T CELL DEPLETION; TRANSPLANTATION TOLERANCE; VACCINATION;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES;

EID: 34347231520     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.008     Document Type: Article

References (43)

1. Billingham R.E., Brent L., and Medawar P.B. "Actively acquired tolerance" of foreign cells. Nature 172 (1953) 603-606
2. Owen R.D. Immunogeneic consequences of vascular anastomoses between bovine twins. Science 102 (1945) 400-401
3. Owens M.L., Maxwell J.G., Goodnight J., and Wolcott M.W. Discontinuance of immunosuppression in renal transplant patients. Arch Surg 110 (1975) 1450-1451
4. Uehling D.T., Hussey J.L., Weinstein A.B., Wank R., and Bach F.H. Cessation of immunosuppression after renal transplantation. Surgery 79 (1976) 278-282
5. Main J.M., and Prehn R.T. Successful skin homografts after the administration of high dosage X radiation and homologous bon marrow. J Natl Cancer Inst 15 (1955) 1023-1028
6. Ildstad S.T., and Sachs D.H. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307 (1984) 168-170
7. Clarkson M.R., and Sayegh M.H. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 80 (2005) 555-563
8. Lenschow D.J., Zeng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257 (1992) 789-792
9. Turka L.A., Linsley P.S., Lin H., Brady W., Leiden J.M., Wei R.Q., et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 89 (1992) 11102-11105
10. Larsen C.P., Elwood E.T., Alexander D.Z., Ritchie S.C., Hendrix R., Tucker-Burden C., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
11. Kirk A.D., Harlan D.M., Armstrong N.N., Davis T.A., Dong Y., Gray G.S., et al. CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94 (1997) 8789-8794
12. Adams A.B., Shirasugi N., Jones T.R., Durham M.M., Strobert E.A., Cowan S., et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 174 (2005) 542-550
13. Kirk A.D., Tadaki D.K., Celniker A., Batty D.S., Berning J.D., Colonna J.O., et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 72 (2001) 377-384
14. Larsen C.P., Pearson T.C., Adams A.B., Tso P., Shirasugi N., Strobertm E., et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5 (2005) 443-453
15. Kawai T., Sogawa H., Boskovic S., Abrahamian G., Smith R.N., Wee S.L., et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 4 (2004) 1391-1398
16. Kawai T., Cosimi A.B., Wee S.L., Houser S., Andrews D., Sogawa H., et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 73 (2002) 1757-1764
17. Knechtle S.J., Vargo D., Fechner J., Zhai Y., Wang J., Hanaway M.J., et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 63 (1997) 1-6
18. Torrealba J.R., Fernandez L.A., Kanmaz T., Oberley T.D., Schultz J.M., Brunner K.G., et al. Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection. Transplantation 76 (2003) 524-530
19. Torrealba J.R., Katayama M., Fechner Jr. J.H., Jankowska-Gan E., Kusaka S., Xu Q., et al. Metastable tolerance to rhesus monkey renal transplants is correlated with allograft TGF-beta 1+CD4+ T regulatory cell infiltrates. J Immunol 172 (2004) 5753-5764
20. Bashuda H., Kimikawa M., Seino K., Kato Y., Ono F., Shimizu A., et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest 115 (2005) 1896-1902
21. Mazariegos G.V., Reyes J., Marino I.R., Demetris A.J., Flynn B., Irish W., et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63 (1997) 243-249
22. Roussey-Kesler G., Giral M., Moreau A., Subra J.F., Legendre C., Noel C., et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 6 (2006) 736-746
23. Louis S., Braudeau C., Giral M., Dupont A., Moizant F., Robillard N., et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 81 (2006) 398-407
24. Baeten D., Louis S., Braud C., Braudeau C., Ballet C., Moizant F., et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 17 (2006) 294-304
25. Ballet C., Roussey-Kesler G., Aubin J.T., Brouard S., Giral M., Miqueu P., et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 6 (2006) 2796-2801
26. Kirk A.D., Hale D.A., Cendales L.K., Hoffmann S.C., Kampen R.L., Kleiner D.E., et al. Results from a human tolerance trial using alemtuzumab (Campath-1H) with deoxyspergualin (DSG). Am J Transplant 3 Suppl 5 (2003) S310
27. Pearl J.P., McCoy K.L., Wakefield T., Swanson S.J., Hale D.A., Mannon R.B., et al. Repopulating cells after aggressive lymphocyte depletion are predominantly memory phenotype. Am J Transplant 3 Suppl 5 (2003) S446
28. Kirk A.D., Mannon R.B., Kleiner D.E., Swanson J.S., Kampen R.L., Cendales L.K., et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 80 (2005) 1051-1059
29. Barth R.N., Janus C.A., Lillesand C.A., Radke N.A., Pirsch J.D., Becker B.N., et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 19 (2006) 885-892
30. Tan H.P., Kaczorowski D.J., Basu A., Unruh M., McCauley J., Wu C., et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 6 (2006) 2409-2417
31. Fudaba Y., Spitzer T.R., Shaffer J., Kawai T., Fehr T., Delmonico F., et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 6 (2006) 2121-2133
32. Kawai T., Sachs D.H., Spitzer T.R., Tolkoff-Rubin N., Delmonico F.L., Saidman S.L., et al. Combined kidney and bone marrow transplantation for induction of mixed chimerism and renal allograft tolerance in HLA matched and mismatched recipients. Am J Transplant 5 (2005) 1535
33. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., and Turka L.A. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 166 (2001) 973-981
34. Wu Z., Bensinger S.J., Zhang J., Chen C., Yuan X., Huang X., et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10 (2004) 87-92
35. Valujskikh A. The challenge of inhibiting alloreactive T-cell memory. Am J Transplant 6 (2006) 647-651
36. Adams A.B., Pearson T.C., and Larsen C.P. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 196 (2003) 147-160
37. Walker W.E., Nasr I.W., Camirand G., Tesar B.M., Booth C.J., and Goldstein D.R. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 177 (2006) 5307-5316
38. Chen L., Wang T., Zhou P., Ma L., Yin D., Shen J., et al. TLR engagement prevents transplantation tolerance. Am J Transplant 6 (2006) 2282-2291
39. Lakkis F.G., Arakelov A., Konieczny B.T., and Inoue Y. Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 6 (2000) 686-688
40. Salama A.D., Najafian N., Clarkson M.R., Harmon W.E., and Sayegh M.H. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 14 (2003) 1643-1651
41. VanBuskirk A.M., Burlingham W.J., Jankowska-Gan E., Chin T., Kusaka S., Geissler F., et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 106 (2000) 145-155
42. Newell K.A., and Larsen C.P. Tolerance assays: measuring the unknown. Transplantation 81 (2006) 1503-1509
43. Najafian N., Albin M.J., and Newell K.A. How can we measure immunologic tolerance in humans?. J Am Soc Nephrol 17 (2006) 2652-2663